Leerink Partners Reiterates Buy Rating on SABS
Leerink Partners maintains its Buy rating on SABS with a $12 price target.
Key Points
- Leerink Partners reiterated its Buy rating on SABS with a price target of $12 on June 15, 2026.
- SABS shares are trading at $3.33, with recent insider purchases by key executives.
- Peer funds like Perceptive Advisors significantly increased their SABS holdings.
Leerink Partners reiterated its Buy rating on SABS, setting a price target of $12. This update came on June 15, 2026. Shares of SABS are currently trading at around $3.33.
Other Institutional Activity in SABS
Perceptive Advisors LLC significantly increased its holdings in SABS, adding 5,628,533 shares to end with 6,431,743 shares valued at approximately $24.63 million. Caligan Partners LP also made a substantial purchase, acquiring 7,967,207 shares, fully establishing its position valued at $30.51 million. Meanwhile, VIVO Capital, LLC maintained its stake with 11,420,000 shares valued at about $43.74 million.
SABS Stock Snapshot
Shares of SABS are trading near $3.33. The stock has seen various institutional activities, reflecting interest from multiple funds. The current trading levels and recent analyst recommendations suggest a focus on future growth potential.
Insider Buying and Selling at SAB Biotherapeutics, Inc.
Several insiders at SABS have been active in the market. On February 3, 2026, CEO Samuel Reich purchased 4,800,000 shares, while Chief Financial Officer Lucy To and Chief Operating Officer Christoph Lawrence Bausch each bought 2,400,000 shares. Chief Medical Officer Alexandra Kropotova also acquired 2,400,000 shares on the same day.
Analysts Set New Price Targets
On June 15, 2026, HC Wainwright & Co. reiterated its Buy rating on SABS with a $10 price target. Earlier, on May 22, 2026, Citigroup initiated coverage with a Buy rating and an $11 target, while Jefferies also started coverage with a Buy rating and the same $11 target on May 20, 2026.
About SABS
SABS operates in the biotechnology sector, focusing on developing innovative therapies to address unmet medical needs. The company is known for its research and development efforts, aiming to bring new solutions to the healthcare market.
Bottom Line
Leerink Partners' reiterated Buy rating with a $12 target indicates confidence in SABS's future prospects. Investors pay attention to such ratings as they reflect an analyst's view of the company's potential. However, it's important to remember that this is based on past data and may not reflect the current market conditions. Peer fund activities and insider transactions also provide insights into how key players view the company's prospects.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.